Skip to main content
Equibles
NBIX logo

NBIX · Neurocrine Biosciences Inc · Webcasts, Transcripts & Audio

Track NBIX — free

Use NBIX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NBIX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$144.19 -1.81 (-1.24%) Q2 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$14.84B
Shares
101.65M
Volume · Oct 28 417.94K Avg daily vol (3M) 1.32M

Neurocrine Biosciences Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Neurocrine Biosciences Inc (NBIX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-02
Neurocrine Biosciences Inc (NBIX) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
Neurocrine Biosciences Inc (NBIX) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Neurocrine Biosciences Inc (NBIX) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Neurocrine Biosciences Inc (NBIX) Q2 2026 Earnings Call Transcript
Confident tone Vicaat XR (Soleno acquisition) integration Crenessity launch in CAH Ingrezza (valbenazine) performance and guidance raise
Revenue
$959.00M
▲ 39.5% YoY
Diluted EPS
$1.39
▲ 31.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-26
Neurocrine Biosciences Inc (NBIX) May 26, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-26
Neurocrine Biosciences Inc (NBIX) May 26, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-05
Neurocrine Biosciences Inc (NBIX) May 5, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Neurocrine Biosciences Inc (NBIX) Q1 2026 Earnings Call Transcript
Confident tone INGREZZA commercial performance and TD market opportunity R&D pipeline and upcoming data readouts Payer seasonality and reimbursement dynamics
Revenue
$814.50M
▲ 42.2% YoY
Diluted EPS
$1.91
▲ 2287.5% YoY
Gross margin
98.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-11
Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Transcript
Confident tone CRENESSITY launch and CAH market development U.S. focus and European business divestiture INGREZZA commercial performance
Revenue
$805.50M*
▲ 28.3% YoY
Gross margin
97.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Transcript
Confident tone INGREZZA commercial momentum CRENESSITY launch Clinical pipeline advancement
Revenue
$794.90M
▲ 27.8% YoY
Diluted EPS
$2.04
▲ 64.5% YoY
Gross margin
98.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Transcript
Confident tone CRENESSITY launch INGREZZA commercial performance Pipeline and R&D Day
Revenue
$687.50M
▲ 16.5% YoY
Diluted EPS
$1.06
▲ 68.3% YoY
Gross margin
98.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Transcript
Confident tone INGREZZA Commercial Performance CRENESSITY Launch Pipeline and R&D
Revenue
$572.60M
▲ 11.1% YoY
Diluted EPS
$0.08
▼ 81% YoY
Gross margin
98.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-06
Neurocrine Biosciences Inc (NBIX) Q4 2024 Earnings Call Transcript
Revenue
$627.70M*
▲ 21.8% YoY
Gross margin
98.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Transcript
Confident tone Crinecerfont launch preparation for CAH INGREZZA commercial performance and TD market opportunity Pipeline progression - NBI-'845 and NBI-'568
Revenue
$622.10M
▲ 24.7% YoY
Diluted EPS
$1.24
▲ 51.2% YoY
Gross margin
98.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Neurocrine Biosciences Inc (NBIX) Q2 2024 Earnings Call Transcript
Confident tone Crinecerfont Launch Preparation INNGREZZA Commercial Momentum INNGREZZA Lifecycle and Formulation Expansion
Revenue
$590.20M
▲ 30.4% YoY
Diluted EPS
$0.63
▼ 33.7% YoY
Gross margin
98.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript
Confident tone Crinecerfont NDA and launch prep INGREZZA franchise growth NBI-845 (AMPA) in major depressive disorder
Revenue
$515.30M
▲ 22.6% YoY
Diluted EPS
$0.42
Gross margin
98.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-07
Neurocrine Biosciences Inc (NBIX) Q4 2023 Earnings Call Transcript
Confident tone Ingrezza franchise growth 2024 financial guidance and SG&A leverage R&D pipeline expansion
Revenue
$515.20M*
▲ 25% YoY
Gross margin
98.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Neurocrine Biosciences Inc (NBIX) Q3 2023 Earnings Call Transcript
Revenue
$498.80M
▲ 28.6% YoY
Diluted EPS
$0.82
▲ 18.8% YoY
Gross margin
97.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Neurocrine Biosciences Inc (NBIX) Q2 2023 Earnings Call Transcript
Revenue
$452.70M
▲ 19.7% YoY
Diluted EPS
$0.95
Gross margin
97.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Neurocrine Biosciences Inc (NBIX) Q1 2023 Earnings Call Transcript
Revenue
$420.40M
▲ 35.4% YoY
Diluted EPS
$-0.79
▼ 664.3% YoY
Gross margin
98.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-06
Neurocrine Biosciences Inc (NBIX) Q4 2022 Earnings Call Transcript
Revenue
$412.00M*
▲ 32.1% YoY
Gross margin
98.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Neurocrine Biosciences Inc (NBIX) Q3 2022 Earnings Call Transcript
Revenue
$387.90M
▲ 31% YoY
Diluted EPS
$0.69
▲ 200% YoY
Gross margin
98.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Neurocrine Biosciences Inc (NBIX) Q2 2022 Earnings Call Transcript
Revenue
$378.20M
▲ 30.9% YoY
Diluted EPS
$-0.18
▼ 141.9% YoY
Gross margin
98.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Neurocrine Biosciences Inc (NBIX) Q1 2022 Earnings Call Transcript
Revenue
$310.60M
▲ 31.3% YoY
Diluted EPS
$0.14
▼ 57.6% YoY
Gross margin
98.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-06
Neurocrine Biosciences Inc (NBIX) Q4 2021 Earnings Call Transcript
Revenue
$312.00M*
▲ 25.9% YoY
Gross margin
98.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-01
Neurocrine Biosciences Inc (NBIX) Q3 2021 Earnings Call Transcript
Revenue
$296.00M
▲ 14.5% YoY
Diluted EPS
$0.23
Gross margin
98.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Neurocrine Biosciences Inc (NBIX) Q2 2021 Earnings Call Transcript
Revenue
$288.90M
▼ 4.5% YoY
Diluted EPS
$0.43
▼ 46.9% YoY
Gross margin
98.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Neurocrine Biosciences Inc (NBIX) Q1 2021 Earnings Call Transcript
Revenue
$236.60M
▼ 0.2% YoY
Diluted EPS
$0.33
▼ 15.4% YoY
Gross margin
98.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-08
Neurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call Transcript
Revenue
$247.90M
▲ 1.6% YoY
Diluted EPS
$3.58
▲ 922.9% YoY
Gross margin
98.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Neurocrine Biosciences Inc (NBIX) Q3 2020 Earnings Call Transcript
Revenue
$258.50M
▲ 16.4% YoY
Diluted EPS
$-0.62
▼ 210.7% YoY
Gross margin
99.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Date not confirmed
Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript
Revenue
$302.40M
▲ 64.8% YoY
Diluted EPS
$0.81
▲ 50% YoY
Gross margin
99.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Neurocrine Biosciences Inc (NBIX) Q1 2020 Earnings Call Transcript
Revenue
$237.10M
▲ 71.3% YoY
Diluted EPS
$0.39
Gross margin
99.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-05
Neurocrine Biosciences Inc (NBIX) Q4 2019 Earnings Call
Revenue
$244.10M
▲ 85.6% YoY
Diluted EPS
$0.35
▲ 84.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–33 of 33 webcasts
Key facts CIK 914475 CUSIP 64125C109 13F (30d) 195 filings 184 filers Visit website Investor relations